Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Snap (SNAP) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Snap between April 29, 2025, to August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Ea ...

Core Viewpoint - A class action lawsuit has been filed against PubMatic, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial outlook during the class period from February 27, 2025, to August 11, 2025 [6]. Allegation Details - The lawsuit claims that PubMatic failed to disclose significant adverse facts, including a major demand-side platform (DSP) buyer shifting clients to a new platform, resulting in reduced ad spend and revenue for PubMatic [6]. - The complaint highlights that the positive statements made by the company regarding its business were misleading and lacked a reasonable basis due to these undisclosed issues [6]. Financial Impact - Following the release of its second quarter 2025 financial report on August 11, 2025, which revealed a reduction in ad spend from a top DSP partner, PubMatic's stock price dropped by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the Class Period from January 30, 2025, to July 23, 2025 [1][7]. Allegation Details - Defendants overstated Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, softening global sales, and product oversupply on Dow's business were understated [3]. - Public statements made by the Defendants were materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Dow shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina, and specializes in commercial and securities litigation [5].

Core Points - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, statements made by the defendants about the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Performance - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Legal Actions - Investors who purchased Snap securities between April 29, 2025, and August 5, 2025, are encouraged to contact the law firm Bragar Eagel & Squire to discuss their legal rights and options [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 20, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [8] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [8] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price drop of nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4] - The law firm offers no cost or obligation for consultations regarding the lawsuit [4]

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making false and misleading statements regarding its product Pylarify and its competitive position during the specified Class Period [7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately prepared to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 10, 2025 [7].

Core Points - A class action lawsuit has been filed against Quantum Corporation (NASDAQ: QMCO) for allegedly making false and misleading statements regarding its financial practices [3][7] - The lawsuit claims that Quantum improperly recognized revenue for the fiscal year ended March 31, 2025, necessitating a restatement of financial statements for the fiscal third quarter ended December 31, 2024 [3][7] - Investors who acquired Quantum securities between November 15, 2024, and August 18, 2025, are encouraged to contact the law firm Bragar Eagel & Squire for potential legal recourse [4][7] Allegation Details - The lawsuit alleges that Quantum Corporation's statements about its business, operations, and prospects were materially false and misleading due to improper revenue recognition [3] - The failure to disclose these issues resulted in damages to investors when the true details became public [3] Next Steps - Investors who suffered losses and wish to learn more about the claims or have questions are advised to contact the law firm directly [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 3, 2025 [7]

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentation regarding its New Drug Application for oxylanthanum carbonate [8] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [8] - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [8] Allegation Details - The lawsuit alleges that Unicycive's management assured investors of the company's ability to satisfy FDA requirements, which was later revealed to be overstated [8] - On June 10, 2025, Unicycive disclosed that the FDA identified deficiencies in compliance at a third-party manufacturing vendor, leading to a stock price drop of over 40% [8] - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same deficiencies, Unicycive's stock fell nearly 30%, closing at $4.77 per share [8] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [4] - The firm emphasizes that there is no cost or obligation for investors to inquire about their rights [4]